BACKGROUND: The aim was to evaluate long-term efficacy, quality of life, and safety in @entity31 @entity1 who received infliximab during the @entity30639 extension studies. METHODS: Adults with moderate-to-severely active @entity31 in the 54-week @entity15588 and 30-week @entity12868 studies who achieved benefit from infliximab were eligible to participate in extension studies and receive up to 3 additional years of therapy. @entity1 received randomized study medication until all sites were unblinded; placebo-treated @entity1 were discontinued. @entity1 receiving 5 or 10 mg/kg infliximab continued to receive open-label infliximab every 8 weeks. @entity1 receiving infliximab 10 mg/kg could decrease to 5 mg/kg; @entity1 receiving infliximab 5 mg/kg could increase to 10 mg/kg if response was lost. RESULTS: A total of 229 of 484 infliximab-treated @entity1 from the @entity15588 and @entity12868 main studies entered the long-term extensions. Overall, 70 (30.6%) @entity1 discontinued infliximab infusions for adverse events (24 [10.5%]), lack of efficacy (11 [4.8%]), required a colectomy (1 [0.4%]), or for other reasons (34 [14.8%]). Proportions of @entity1 whose Physician's Global Assessment scores were indicative of no or mild disease (score = 0 or 1) were maintained during the extension studies; 76.5% at Extension week 0 and ranged between 90.0% and 94.3% through Extension week 152. Improvement in Inflammatory Bowel Disease Questionnaire scores observed in the main studies was maintained. During the long-term extension, the infliximab safety profile was consistent with that of the main studies; no new or unexpected safety signals were observed. CONCLUSIONS: Long-term treatment with infliximab for up to 3 additional years was effective and well tolerated.

Long-term infliximab maintenance therapy for XXXX : the @entity30639 extension studies.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity30639 :: ('10758;6351', 'Gene') :: ['ACT-1 and -2'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity12868 :: ('6351', 'Gene') :: ['ACT-2'] @entity15588 :: ('10758', 'Gene') :: ['ACT-1']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
